Tirzepatide
5 mg
Dual GIP/GLP-1 Receptor Agonist (Mounjaro analogue)
Tirzepatide
Dual GIP/GLP-1 receptor agonist for advanced metabolic research.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It represents a first-in-class approach to metabolic research by targeting two incretin receptors simultaneously. Research interest has surged due to its unique dual-agonist mechanism.
Specifications
- SKU
- TIRZ-5MG
- Size
- 5 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
Studies show Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic effects on metabolic parameters. Preclinical data demonstrates superior glycaemic control and body weight reduction compared to selective GLP-1 agonists alone. Its pharmacokinetic profile supports once-weekly research dosing protocols.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)